Display options
Cite
Marchesi E, Cagnazzo C, Quattrini I, et al. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clin Sarcoma Res. 2017;7:4doi: 10.1186/s13569-017-0068-4.
Marchesi, E., Cagnazzo, C., Quattrini, I., Leopardi, M. P., Villa, C., Grignani, G., D'Ambrosio, L., Stacchiotti, S., Casali, P. G., & Picci, P. (2017). How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clinical sarcoma research, 74. https://doi.org/10.1186/s13569-017-0068-4
Marchesi, Emanuela, et al. "How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience." Clinical sarcoma research vol. 7 (2017): 4. doi: https://doi.org/10.1186/s13569-017-0068-4
Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D'Ambrosio L, Stacchiotti S, Casali PG, Picci P. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clin Sarcoma Res. 2017 Feb 28;7:4. doi: 10.1186/s13569-017-0068-4. eCollection 2017. PMID: 28261443; PMCID: PMC5329913.
Copy Download .nbib Format: NLM
Share it on

Clin Sarcoma Res. 2017 Feb 28;7:4. doi: 10.1186/s13569-017-0068-4. eCollection 2017.

How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

Clinical sarcoma research

Emanuela Marchesi, Celeste Cagnazzo, Irene Quattrini, Martina Piccinni Leopardi, Chiara Villa, Giovanni Grignani, Lorenzo D'Ambrosio, Silvia Stacchiotti, Paolo Giovanni Casali, Piero Picci

Affiliations

  1. Italian Sarcoma Group, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy.
  2. Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
  3. Chemotherapy Unit, Orthopedic Rizzoli Institute, Bologna, Italy.
  4. Adult Mesenchymal Tumour and Rare Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  5. Laboratory of Experimental Oncology, Orthopedic Rizzoli Institute, Bologna, Italy.

PMID: 28261443 PMCID: PMC5329913 DOI: 10.1186/s13569-017-0068-4

Abstract

BACKGROUND: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory requirements, the chance to increase the number of trials with other cooperative groups and an interest from pharmaceutical companies in supporting independent research, generated the need of an internal service for research management.

METHODS AND RESULTS: In 2010, ISG implemented in its organization a Clinical Trial Unit (CTU). The CTU was appointed to fully manage Clinical Trial Operations, to guarantee regulation compliance and provide a central support to the investigators, fostering a collaboration both at national and international level. In 2016 ISG promoted 25 studies in about 120 centers, with a fivefold increase in the last 5 years: 68% were interventional and 32% observational. Nine of the 17 interventional studies (52%) were supported by pharmaceutical companies, while 4 (24%) were funded by European Commission within specific projects on sarcomas and 4 (24%) were supported by the ISG itself.

CONCLUSION: The contribution of ISG researchers to the international community was striking from the earliest years of the ISG creation. The challenges of the regulatory clinical research scenario, which imposes solid and hard-fast methodology with deep knowledge and expertise, highlighted the need to identify qualified and dedicated experts able to run and follow the multifaceted aspects of trials. Our analysis demonstrated how this model has led to a growth in competitiveness of the group. The collaboration between clinicians and CTU made possible to support the research with high scientific and ethical standards and to increase the number of trials, sites and overall enrolled patients. The reduced time for approvals, the continuous support to sites, the increased speed in data collection and analysis make the ISG research attractive for pharmaceutical industries, despite the problems that have characterized the independent research in the last years. The ability to fully manage and oversight Clinical Operations and the high quality of delivered services, have led the ISG to be recognized as a reliable partner and coordinator within the international sarcoma networks.

References

  1. BMJ. 2003 Jul 5;327(7405):47-9 - PubMed
  2. Ann Oncol. 2014 Sep;25 Suppl 3:iii113-23 - PubMed
  3. BMJ. 2014 Nov 24;349:g6802 - PubMed
  4. Ann Oncol. 2015 Feb;26(2):300-6 - PubMed
  5. Eur J Cancer. 2011 Nov;47(17):2493-511 - PubMed
  6. Ann Oncol. 1992 Apr;3 Suppl 2:S13-7 - PubMed
  7. Lancet Oncol. 2016 Feb;17(2):e62-9 - PubMed
  8. Ital J Orthop Traumatol. 1988 Mar;14(1):23-39 - PubMed
  9. Clin Sarcoma Res. 2012 Oct 04;2(1):14 - PubMed
  10. Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9 - PubMed
  11. Lancet Oncol. 2016 Feb;17(2):e70-80 - PubMed
  12. Adv Exp Med Biol. 2010;686:285-303 - PubMed
  13. Eur J Cancer. 2015 Feb;51(3):271-81 - PubMed
  14. Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9 - PubMed

Publication Types